Theorem Clinical Research

R&D Trends

Evotec partners to develop multiple sclerosis treatments

Tuesday, September 30, 2014 10:00 AM

Evotec, a German-based drug discovery alliance and development partnership company, has entered into three novel research projects for the treatment of multiple sclerosis (MS), supported by research funds from the German Federal Ministry of Education and Research (BMBF).

More... »


Catalent, Cingulate Therapeutics ink agreement for new ADHD treatments

Tuesday, September 30, 2014 09:00 AM

Catalent Pharma Solutions, headquartered in Somerset, N.J., has reached an exclusive development and licensing agreement with Cingulate Therapeutics (CTx), a Morristown, N.J.-based, privately held biopharmaceutical company, to support development of a series of new prescription pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) using Catalent's OSDrC OptiDose drug delivery platform.

More... »


BioMotiv, Takeda partner for medical innovation

Monday, September 29, 2014 01:06 PM

Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has invested in BioMotiv, a therapeutic accelerator company associated with the Ohio-based Harrington Project for Discovery & Development, and they have partnered to identify and develop pioneering medical innovations.

More... »

Medimmune, Cancer Research U.K. establish laboratory for biologic cancer medicines

Friday, September 26, 2014 03:24 PM

MedImmune, AstraZeneca’s global biologics R&D arm, and Cancer Research U.K., with its commercial arm Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, U.K. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period.

More... »

Soligenix awarded $24.7M NIAID contract for heat stable RiVax vaccine

Friday, September 26, 2014 03:05 PM

Soligenix, a Princeton, N.J.-based late-stage biopharmaceutical company developing products that address unmet medical needs in inflammation, oncology and biodefense, has been awarded a contract valued at up to $24.7 million inclusive of options by the U.S. Department of Health and Human Service's NIH, specifically funded by the National Institute of Allergy and Infectious Diseases (NIAID). The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

More... »

Thermo Fisher Scientific inks agreement with GlaxoSmithKline, Pfizer

Friday, September 26, 2014 03:01 PM

Thermo Fisher Scientific, a Waltham, Mass.-based healthcare equipment company, has inked an agreement with GlaxoSmithKline and Pfizer to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs.

More... »

Aethlon Medical, Exosome Sciences to collaborate with BU CTE Center

Friday, September 26, 2014 03:00 PM

Aethlon Medical and its New Jersey-based diagnostic subsidiary Exosome Sciences (ESI) have established a clinical collaboration with the Boston University (BU) CTE Center to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.

More... »

Baxter, Merrimack Pharmaceuticals ink agreement for MM-398

Thursday, September 25, 2014 12:50 PM

Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as nal-IRI. Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the U.S. and Taiwan, and Merrimack retains commercialization rights in the U.S.; the rights in Taiwan are held separate/news-online/company/EMAly.

More... »

Atara Biotherapeutics, Memorial Sloan-Kettering Cancer Center ink agreement

Wednesday, September 24, 2014 01:25 PM

Atara Biotherapeutics, a California-based, privately held drug development company, has entered into an exclusive option agreement with New York’s Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies, consisting of:

More... »

Tekmira joins consortium conducting Ebola virus trials in West Africa

Wednesday, September 24, 2014 01:22 PM

Tekmira Pharmaceuticals, a British Columbia-based developer of RNA interference (RNAi) therapeutics, is collaborating with an international consortium to provide an RNAi-based investigational therapeutic for expedited clinical studies in West Africa.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs